Wegovy (semaglutide injection once weekly) / Novo Nordisk, Emcure - LARVOL DELTA

Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy and Ozempic (GlobeNewswire) - "Novo Nordisk announced today that it has filed a lawsuit against telehealth company Hims & Hers ('Hims'), for infringing US Patent 8,129,343 with Hims’ compounded semaglutide products for the US market....Novo Nordisk takes decisive legal action to stop Hims’ illegal conduct, protect public health, and defend the scientific innovations that deliver better health outcomes to Americans living with serious chronic diseases like obesity and diabetes. Novo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that infringe our patents, and is seeking to recover damages."

Corporate lawsuit • Obesity • Type 2 Diabetes Mellitus

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug and one day after the Food and Drug Administration threatened to restrict access to the ingredients needed to copy popular weight-loss medications. (ABC News) - "Hims had said Thursday that it would offer a compounded version of the new Wegovy pill that drugmaker Novo Nordisk just began selling last month. Novo immediately threatened to sue Hims, and then the FDA said Friday that it plans to take decisive steps to limit access to the active ingredients in popular GLP-1 drugs like Wegovy, Ozempic and Zepbound. Hims' own website still touted the new semaglutide pill offering Saturday afternoon — hours after it announced on X that it will no longer sell the medicine....Hims didn’t say Saturday whether it will make any changes to the compounded versions of injectable weight-loss medications it has been selling as a result of the FDA action."

Commercial • Obesity

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight (clinicaltrials.gov) - P3 | N=809 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

PharmaZee GLP-1 Prescription Information Updated as Novo Nordisk Raises Compounding Concerns and Consumer Interest in Telehealth Semaglutide Access Grows in 2026 (The Manila Times) - "As consumer interest in prescription weight management treatment access through telehealth platforms continues to grow heading into 2026, updated service disclosures for PharmaZee-a prescription-only offering-have recently become publicly available."

Commercial • Obesity • Type 2 Diabetes Mellitus

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (5 February 2026) updated product information for healthcare professionals and patients regarding the risk of the very rare occurrence of non-arteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide. (GOV.UK) - "Patients taking semaglutide who notice a change in their eyesight, such as sudden impairment to their vision, or if their eyesight gets worse very quickly in one or both eyes, should urgently attend eye casualty (if available in the area) or A&E."

European regulatory • Obesity • Type 2 Diabetes Mellitus

Novo Nordisk says generic Ozempic, Wegovy will slow sales in Canada (Global News) - "The Denmark-based pharmaceutical company behind brand names like Wegovy and Ozempic said in an earnings report on Wednesday that it expects somewhat weaker demand in 2026, citing 'intensifying competition' as its grip on the Canadian market starts to weaken as part of its 'Semaglutide Loss of Exclusivity' or 'Sema LOE'. This comes after Health Canada last month approved several generic treatment options for reducing risks from diabetes and helping to manage weight."

Generic launch • Sales • Diabetes • Obesity

Domestic sales grew 15.4 percent to Rs 1,025 crore, led by chronic therapies such as cardiovascular and diabetes, and supported by new initiatives. (Moneycontrol) - "A major contributor this quarter was the launch of Poviztra, a biological injectable semaglutide licensed from Novo Nordisk, giving Emcure a foothold in India’s fast‑growing weight‑management and obesity‑care market."

Sales • Cardiovascular • Obesity

Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its ​rival medicines, as the Danish drugmaker fought for market share.... (Yahoo Finance) - "The data from advertising tracking firm MediaRadar, ‌which has not been previously reported, shows Novo spent an estimated $316 million advertising its weight-loss drug Wegovy in the U.S. and $169 million on diabetes medication Ozempic from January through September last ‌year. That's up 54% and 44%, respectively from the same period in 2024. Indianapolis-based market leader Eli Lilly spent about $131 million advertising obesity treatment Zepbound in the same period versus $2 million in 2024. It spent $83 million promoting diabetes medicine Mounjaro. Combined, Novo spent about $487 million and Lilly an estimated $214 million on U.S. ads for these drugs."

Commercial • Diabetes • Obesity

GLP-1 Medicines and Mental Health Changes (clinicaltrials.gov) - P=N/A | N=90 | Completed | Sponsor: University of California, San Diego

New trial • CNS Disorders • Depression • Genetic Disorders • Mood Disorders • Obesity • Psychiatry

Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025 (The Manila Times) - "Sales in International Operations increased by 10% in Danish kroner (14% at CER). Sales within Obesity and Diabetes care increased by 7% in Danish kroner to DKK 289.5 billion (10% at CER), mainly driven by Obesity care growth of 26% in Danish kroner (31% at CER) and GLP-1 diabetes sales growing 2% in Danish kroner (6% at CER). Rare disease sales increased by 5% in Danish kroner (9% at CER)."

Sales • Obesity • Type 2 Diabetes Mellitus

Publix Pharmacy is currently offering savings on select GLP‑1 therapies through a discount card program. (Businesswire) - "For a limited time, eligible Publix Pharmacy customers can have their prescriptions for the newly introduced Wegovy (semaglutide) 1.5 mg or 4 mg tablet filled at pricing starting as low as $149 per month, and Wegovy and Ozempic (semaglutide) 0.25 mg and 0.5 mg injectables starting as low as $199 per month."

Commercial • Obesity

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight (clinicaltrials.gov) - P3 | N=460 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Genetic Disorders • Obesity

On 29 January 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Kayshild, intended for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH). (European Medicines Agency) - "Kayshild will be available as a 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg solution for injection in pre-filled pens."

CHMP • Metabolic Dysfunction-Associated Steatohepatitis

Indian drugmaker Dr Reddy’s...said that it has received an approval from the country’s drug regulator to manufacture and sell the generic version of blockbuster diabetes drug Ozempic. (Pharmalive) - "The company plans to sell 12 million injectable Semaglutide pens in the first year of launch. The patent for Semaglutide, the active ingredient in Novo Nordisk’s (NOVOb.CO) drugs Wegovy and Ozempic, expires in March 2026, allowing Reddy’s and other Indian generic drugmakers, racing to grab a share of the booming weight-loss market, to launch generic versions of the drugs."

Approval • Patent expiry • Diabetes • Obesity

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes (clinicaltrials.gov) - P3 | N=1200 | Recruiting | Sponsor: Kailera | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

GLIMMER: Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass (clinicaltrials.gov) - P=N/A | N=50 | Not yet recruiting | Sponsor: University of Alberta | N=25 ➔ 50 | Trial completion date: Apr 2027 ➔ Apr 2028 | Trial primary completion date: Jan 2027 ➔ Dec 2027

Enrollment change • Trial completion date • Trial primary completion date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Novo Nordisk today announced that its weight-loss drug, Wegovy (semaglutide 2.4mg), is now officially available in Malaysia, offering a new treatment option for adults living with obesity or who are overweight with related health issues. (Malay Mail)

Launch non-US • Obesity

Clinical advice sought on funding Wegovy weight loss drug - Pharmac (1News) - "Pharmac received two applications to fund Wegovy or semaglutide - a GLP-1 receptor agonist for weight loss...Pharmac director of advice and assessment David Hughes said guidance was expected to be published later this month...However, that would reduce the cost to AU$25 (NZ$29) per script or AU$7.70 (NZ$9) for a concession card holder...Wegovy costs $459.99 per month in New Zealand....Associate Minister of Health David Seymour could not comment on what Pharmac should or should not fund."

Reimbursement • Cardiovascular • Obesity

JOULE - MARS: JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity (clinicaltrials.gov) - P4 | N=74 | Recruiting | Sponsor: McMaster University | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

The UK’s medicines regulator has approved a stronger dose of the weight loss jab Wegovy as demand for the drug is set to soar (The Independent) - "The new 7.2mg dose is three times higher than the current approved dosage of 2.4mg a week, and according to the Medicines and Healthcare products Regulatory Agency (MHRA), it can provide more than 20 per cent weight loss....The latest MHRA approval for Wegovy is based on data from a clinical trial, called Step Up, which evaluated the effect of treatment on patients."

MHRA approval • Obesity

Shed Expands GLP-1 Weight-Loss Offerings with Wegovy Pills via NovoCare (PRNewswire) - "This new offering provides members with flexible, medically supervised options designed to meet patients where they are in their weight-loss journey."

Commercial • Obesity

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) (clinicaltrials.gov) - P2 | N=381 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance (AASLD) - "Semaglutide showed a favorable hepatic safety profile in the ESSENCE trial, with no discontinuations due to liver enzyme elevations. Routine hepatic panels are recommended only as clinically indicated. The most common adverse events were gastrointestinal (nausea, diarrhea, constipation, vomiting), generally mild and transient; patient education and dose titration help improve tolerance...Lifestyle modification remains the cornerstone of MASLD/MASH management alongside semaglutide. Combination use with resmetirom at the dose of 2.4 mg/week has not been studied."

Clinical guideline • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

Weight loss drug Wegovy to be listed on PBS (Yahoo News) - "Wegovy will be heavily subsidised for Australians with severe obesity, who have also experienced a cardiovascular event, like a heart attack or stroke....It is set to be listed on the Pharmaceutical Benefits Scheme (PBS), meaning it will be subject to a newly introduced maximum price cap for all drugs on the subsidy scheme....As of January 1, the maximum price of a PBS prescription has been price-capped at $25, and $7.70 for pensioners and concession card holders."

Reimbursement • Obesity

Weight Loss Pill Wegovy Now Available On Amazon Pharmacy In The U.S. (NDTV) - "Amazon Pharmacy has begun offering Novo Nordisk's Wegovy weight-loss pill through its online platform and plans to extend availability through physical pharmacy kiosks in the coming weeks....Amazon said eligible customers covered under commercial insurance plans could pay as little as 25 USD for a month's supply of the weight-loss pill, while those without insurance coverage would have the option to purchase it directly, with prices beginning at 149 USD per month."

Commercial • Obesity